Literature DB >> 3987557

Absorption, distribution and elimination of felodipine in man.

B Edgar, K J Hoffmann, P Lundborg, C G Regårdh, O Rönn, L Weidolf.   

Abstract

The objectives of these investigations were to study the absorption and disposition characteristics of felodipine in young healthy male volunteers following acute administration of different intravenous and oral doses, and to study urinary metabolites of [14C]felodipine following oral administration. Felodipine is rapidly and extensively absorbed from the gastrointestinal tract but owing to presystemic elimination, probably primarily in the liver, only 15% on average is systemically available. The systemic availability is independent of the oral dose in the 5 to 40 mg dose interval. The major fraction of the felodipine dose is localised extravascularly with a volume of distribution of about 10 L/kg. Less than 1% is confined to the blood. Felodipine is extensively bound to plasma proteins (greater than 99%). The mean elimination half-life of felodipine is greater than 10 hours. The urinary metabolic pattern of felodipine, using high pressure liquid chromatography, reveals 3 major metabolites (carboxylic acids of oxidised felodipine) in human urine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987557     DOI: 10.2165/00003495-198500292-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Determination of felodipine in plasma by capillary gas chromatography with electron capture detection.

Authors:  M Ahnoff
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

2.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse.

Authors:  L Weidolf; K O Borg; K J Hoffmann
Journal:  Xenobiotica       Date:  1984-08       Impact factor: 1.908

  3 in total
  18 in total

1.  A population study of the pharmacokinetics of felodipine.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

Authors:  S Landahl; B Edgar; M Gabrielsson; M Larsson; B Lernfelt; P Lundborg; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

5.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

7.  Pharmacokinetic interactions between felodipine and metoprolol.

Authors:  S R Smith; M R Wilkins; D B Jack; M J Kendall; S Laugher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of felodipine. A summary.

Authors:  B Edgar; P Lundborg; C G Regårdh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

9.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 10.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.